title: Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.
abstract: The treatment of diffuse large B-cell lymphoma with chemotherapy was retrospectively evaluated in 348 patients who had received at least three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like, ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)-like or CHVmP-BV (cyclophosphamide, hydroxorubicin, Vm-26, prednisone, vincristine and bleomycin) treatment in Belgium between 1995 and 2000. In our sample, the proportion who received each of the three regimens was 78.4, 16.4, and 5.2%, respectively. Of those prescribed CHOP-like regimens, 15% received <80% average relative dose intensity (ARDI). In 210 patients treated with CHOP-21 (77% of the CHOP-like group), median survival was 7.08 years in those who received >90% of the ARDI, significantly longer than in those who received < or = 90% of the ARDI (p = 0.002). Dose reductions and/or delays, mainly due to hematological toxicities, resulted in a reduction in treatment intensity. These data indicate that patient outcome is improved when the intensity of chemotherapy treatment is optimal.
authors.affiliation: Department of Haematology, University Hospital of Mont-Godinne, Yvoir, Belgium. andre.bosly@sang.ucl.ac.be
authors.forename: A
authors.initials: A
authors.lastname: Bosly
authors.forename: D
authors.initials: D
authors.lastname: Bron
authors.forename: A
authors.initials: A
authors.lastname: Van Hoof
authors.forename: R
authors.initials: R
authors.lastname: De Bock
authors.forename: Z
authors.initials: Z
authors.lastname: Berneman
authors.forename: A
authors.initials: A
authors.lastname: Ferrant
authors.forename: L
authors.initials: L
authors.lastname: Kaufman
authors.forename: M
authors.initials: M
authors.lastname: Dauwe
authors.forename: G
authors.initials: G
authors.lastname: Verhoef
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000493:pharmacokinetics; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008223:Lymphoma / Q000145:classification / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality; D018579:Patient Selection; D011241:Prednisone / Q000008:administration & dosage / Q000493:pharmacokinetics; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D014751:Vindesine / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D001761:Bleomycin; D016179:Granulocyte Colony-Stimulating Factor; D004317:Doxorubicin; D003520:Cyclophosphamide; D014751:Vindesine; D011241:Prednisone